Post by Confo Therapeutics

We are pleased to share that our CEO, Cedric Ververken, will be attending the Jefferies Global Healthcare Conference in New York, taking place June 2–4, 2026.   At Confo Therapeutics, we are advancing a differentiated pipeline of GPCR-targeted therapeutics focused on metabolic and endocrine diseases. Our programs include CFTX-2034, our SSTR5 agonist antibody for as post-bariatric hypoglycemia, as well as innovative approaches to obesity, such as our GPR75 antagonist program. Our most advanced compound, CFTX-1554, is a potential therapy for chronic pain which is being evaluated in Phase 2 by our partner Lilly.   Cedric looks forward to engaging with investors to discuss how Confo is advancing breakthrough GPCR-targeted therapies. If you will be attending Jefferies and would like to connect, please reach out to arrange a meeting.   #ConfoTherapeutics #JefferiesHealthcare #Biotech #GPCR #Obesity #Endocrinology #DrugDiscovery #Partnering